|0.869|| +0.0051 / +0.59%|
Services to the Health Industry
Interpace Diagnostics Group, Inc. provides commercialization services to biopharmaceutical companies. It focuses on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for patient diagnosis and management. The company offers commercialized molecular tests which include PancraGen, ThyGenX, and ThyraMIR. PancraGen for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.
|Jack E. Stover||President, Chief Executive Officer & Director|
|Glenn Gershon||Senior Vice President-Operations|
|James Early||Chief Financial Officer|
|Sydney D. Finkelstein||Chief Scientific Officer|
|Sara A. Jackson||Vice President-Clinical Development|